Skip to main content
Premium Trial:

Request an Annual Quote

Larry Hill Replaces Joseph Limber at Bankrupt Deltagen; Elizabeth Song, Margus Annuk New VPs at EGeen; Joseph Smith, Russel Enns Go to Cepheid

NEW YORK, July 2 - Larry Hill has been appointed CEO of Deltagen in the wake of its Chapter 11 bankruptcy, and Daniel Ratto has been appointed chief financial officer, the company announced late last Friday.

 

Hill, a principal at the corporate restructuring and management firm Hickey & Hill, will head up the company during its reorganization.

 

Joseph Limber, a former CEO of Aclara who was appointed CEO of Deltagen in April, stepped down in mid-June, along with John Varian, the company's interim chief financial officer. The two left when it became apparent that the company would not be able to close its Series A financing. 

 

Deltagen, of Redwood City, Calif., also announced that it reduced its workforce to 28 employees: The company said in a statement that it filed for bankruptcy due to "actions taken by" its competitor Lexicon Genetics as well as "the inability to develop a sustainable revenue base that would support its operational needs."

 


 

Elizabeth Song has been appointed vice president of business development and Margus Annuk is the new director of clinical development at EGeen, of Foster City, Calif., the company said today.
 
Song comes to Egeen, which does association studies using DNA from the Estonian Genome Project, from Lynx Therapeutics, where she was director of business development. Prior to this time, Song was director of viral research at Virologix, and senior scientist at Chiron.
 

Annuk was previously an associate preofessor and head of surgical anatomy at Tartu University in Estonia, where he received his MD degree. He has also done research in renal diseases and transplants at University Hospital in Uppsala, Sweden.


 

Joseph Smith has been appointed vice president and general counsel, and Russel Enns has been named vice president of regulatory and clinical affairs at Cepheid, the company said June 30.

 

Smith was most recently vice president, business development, at Applied Biosystems. Prior to that, he was ABI's vice president of Intellectual Property, where he formed the legal department in 1989. He also was previously a partner at the IP law firms of Wiseman, Jones, and Smith, and Boone, Fox, and Jones, and was part of Hewlett-Packard's technical legal department.

 

Enns comes to Cepheid from work as a regulatory consultant, and before that, a position as vice president regulatory affairs, quality system, clinical affairs and medical reimbursement at Abbott subsidiary Vysis. He has also served as vice president of technical affairs at MicroProbe, and director of product development, clinical programs and technical affairs at Gen-Probe.


 

Ian Howes was appointed CFO and senior vice president of finance and administration at Serenex, and Anil Goyal was named vice president of business development.

 

Howes comes to the Durham, NC drug discovery company from Paradigm Genetics, where he was CFO. He has also served as CFO of Analytika, American Care Communities, and EnSys.

 

Goyal joins Serenex from Millennium Pharmaceuticals, where he was senior manager of corporate development. He also served as manager of business development at Genome Therapeutics.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.